Ashfield and IPCAA join forces to find out what HCPs really think about virtual medical congresses in new global study.
Ashfield Meetings & Events (part of UDG Healthcare PLC) and the International Pharmaceutical Congress Advisory Association (IPCAA) today released a study which reveals what healthcare professionals really think about virtual medical congresses.
Through a survey of more than 300 physicians from six countries (US and EU) and across 14 therapy areas, the global healthcare meetings specialist and the advisory association have gained detailed insights that are set to help medical societies, professional congress organizers (PCOs), and the industry consider how to shape virtual congresses of the future.
The study – the second part of which is planned for before the end of 2020 – looks at a variety of elements of the virtual congress, highlighting HCPs’ thoughts on accessibility and technology, how they viewed the online activities including industry symposia and poster sessions, and connecting with industry and peers.
For a summary report of IPCAA and Ashfield’s initial findings, click here.
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.